StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Celgene (CELG) Reports Phase III IMpassion130 Study Met Co-Primary Endpoint of Progression-Free Survival
July 10, 2018 7:32 AM
Celgene Corporation (NASDAQ: CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassi
July 10, 2018 7:30 AM
After-Hours Stock Movers 07/09: (OCX) (XLRN) (HEAR) Higher; (AQXP) (SPRO) (WHD) Lower (more...)
July 9, 2018 5:54 PM
Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 9, 2018 4:53 PM
